(SeaPRwire) – By: Christian Pierce
There is a particular silence in Hollywood that speaks louder than any press junket, and Sony is currently sitting in the middle of it. The studio that rushed 28 Years Later and The Bone Temple into theaters within a single year, a release cadence almost unheard of for a prestige horror property, suddenly has nothing to say about Part 3. No title. No production date. No greenlight announcement. Instead, audiences get Danny Boyle, appearing at the Zurich Film Festival to promote his latest film Ink, offering the kind of reassurance that sounds encouraging until you parse it: the film “will get made because people keep asking about it.” Fan enthusiasm is now apparently the stated business case. That is not how sequels get financed. That is how directors keep hope alive on the festival circuit while spreadsheets get argued over in Culver City. The anxiety here is real and familiar to anyone who watches franchise economics. The Bone Temple made significantly less than 28 Years Later did at the box office. When the second installment of a planned trilogy underperforms the first, the third film stops being a schedule and starts being a negotiation.
The facts on the table are these. Boyle and Alex Garland revived a franchise that had been dormant for years, and they did it aggressively, delivering two films in a planned sequel trilogy inside twelve months. Cillian Murphy’s Jim, the original protagonist of 28 Days Later, returned in the closing moments of The Bone Temple, rushing to rescue young Spike, played by Alfie Williams, and his new ally Kelly, played by Erin Kellyman, from a horde of Infected. That was clearly engineered as a handoff, a narrative bridge designed to merge the legacy audience with the new one. Boyle confirms a script exists, a “very good script” by Garland, reportedly containing “a lot of Cillian Murphy in it,” and the director has committed to returning to helm the finale. What he cannot confirm is timing. In a perfect world, Part 3 would hit theaters sometime in 2027, maintaining the momentum of its predecessors. But momentum is precisely what the box office trajectory of The Bone Temple called into question, and studios do not fast-track nine-figure commitments on the strength of a cliffhanger and good intentions.
Strip away the festival optimism and the commercial loop here is straightforward. Sony bought a trilogy structure, which means it bought an obligation. The first film re-established the brand. The second film spent down some of that goodwill at the box office but preserved the asset by reintroducing Murphy. The third film is where the entire bet either pays off or gets written down, because an unfinished trilogy is a stranded asset: it poisons streaming licensing value, kills long-tail catalogue monetization, and signals to every future filmmaker that Sony abandons commitments mid-arc. Boyle’s comment that the film gets made “because people keep asking about it” is actually the tell. Audience demand is the last remaining leverage point the creative team has, and they are deploying it publicly, deliberately. Expect Sony to greenlight Part 3 on a compressed budget and a longer runway, trading the accelerated release strategy for margin protection, because finishing the trilogy cheaply is still cheaper than explaining to shareholders why the franchise died two-thirds of the way home.
Author bio: Christian Pierce, a chief financial columnist and markets commentator covering studio economics, franchise valuation, and the financing mechanics behind global entertainment properties.